

1 FGF2 and BMP4 influence on FGFR2 dynamics during the segregation of
2 epiblast and primitive endoderm cells in the pre-implantation mouse embryo

3

4 Marcelo D. Goissis^{1,3}, Brian Bradshaw¹, Eszter Posfai^{1,4}, Janet Rossant^{1,2}

5

6 ¹Program in Developmental and Stem Cell Biology, The Hospital for Sick
7 Children, Toronto, ON, Canada

8 ² Department of Molecular Genetics, University of Toronto

9

10 Corresponding Author: Janet Rossant

11 Hospital for Sick Children Research Institute

12 686 Bay Street

13 Toronto

14 Ontario

15 Canada M5G 0A4

16 Email: janet.rossant@sickkids.ca

17

18 ³Current Address: Department of Animal Reproduction, College of Veterinary
19 Medicine and Animal Science, University of Sao Paulo, Brazil

20

21 ⁴Current Address: Princeton University, Department of Molecular Biology,
22 Princeton, NJ, USA

23

24 Short title: FGF and BMP signaling and primitive endoderm differentiation

25

26 **Abstract**

27

28 Specification of the epiblast (EPI) and primitive endoderm (PE) in the
29 mouse embryo involves FGF signaling through the RAS/MAP kinase pathway.
30 FGFR1 and FGFR2 are thought to mediate this signaling in the inner cell
31 mass (ICM) of the mouse blastocyst. In this study, we verified the dynamics of
32 FGFR2 expression through a green fluorescent protein reporter mouse line
33 (FGFR2-eGFP). We observed that FGFR2-eGFP is present in the late 8-cell
34 stage; however, it is absent or reduced in the ICM of early blastocysts. We
35 then correlated GFP expression with GATA6 and NANOG after
36 immunostaining. We detected that GFP is weakly correlated with GATA6 in
37 early blastocysts, but this correlation quickly increases as the blastocyst
38 develops. The correlation between GFP and NANOG decreases throughout
39 blastocyst development. Treatment with FGF from the morula stage onwards
40 did not affect FGFR2-eGFP presence in the ICM of early blastocysts;
41 however, late blastocysts presented FGFR2-eGFP in all cells of the ICM.
42 BMP treatment positively influenced FGFR2-eGFP expression and reduced
43 the number of NANOG-positive cells in late blastocysts. In conclusion, FGFR2
44 is not strongly associated with PE precursors in the early blastocyst, but it is
45 highly correlated with PE cells as blastocyst development progresses,
46 consistent with the proposed role for FGF in maintenance rather than initiating
47 the PE lineage.

48

49

50 **Introduction**

51

52 After fertilization, a series of coordinated events must occur to form an
53 embryo capable of implanting and developing in the uterus. These early
54 events in mammals are characterized by a self-organizing, regulative mode of
55 development (1). During a short period, cells first differentiate into the inner
56 cell mass (ICM) and the trophectoderm (TE), followed by a second
57 differentiation within the ICM into epiblast (EPI) and primitive endoderm (PE).
58 The epiblast will give rise to the embryo proper, while PE will form extra-
59 embryonic endoderm of the visceral and parietal yolk sacs (2,3)

60 Epiblast cells express NANOG, while PE cells first express GATA6,
61 followed by SOX17, GATA4, and PDGFR (4–6). The blastocyst forms around
62 embryonic day 3.25 (E3.25) and at this time ICM cells express both NANOG
63 and GATA6 (5,7). As the blastocyst further develops, NANOG and GATA6
64 expression become mutually exclusive in EPI and PE progenitors,
65 respectively (5,8), and eventually, the PE progenitors will migrate towards the
66 blastocoel cavity to form the PE layer (5). It was shown that both *Nanog* and
67 *Gata6* mutually repress each other, as *Nanog*-null embryos led to the
68 expression of GATA6 in all ICM cells (9) while *Gata6*-null embryos display
69 NANOG in all ICM cells (10,11). Interestingly, PE did not form in *Nanog*-null
70 embryos, as observed by the lack of SOX17 and GATA4, which was caused
71 by a reduction in the expression of *Fgf4* (9).

72 Fibroblast-growth factor signaling through MEK/ERK is central in
73 establishing PE. Deletion of *Grb2* blocked the formation of the PE and led to
74 the expression of NANOG in all ICM cells (4). Inhibition of the MEK/ERK

75 pathway or treatment with excess FGF4 changed the fate of all ICM cells to
76 EPI or PE, respectively (12). This shift in cell fate was reversible if inhibition or
77 activation of the FGF-mediated MEK/ERK signaling occurred before E3.75
78 (12). In addition, deletion of *Fgf4* caused all cells of the ICM to become
79 NANOG-positive at E4.5, although GATA6 was still observed in earlier stages,
80 suggesting that the PE program initiates independently of FGF signaling but
81 requires sustained FGF exposure for lineage choice (7).

82 There is evidence that MEK/ERK signaling is required for
83 phosphorylation and subsequent degradation of NANOG (13). Thus, an
84 interesting question that still poses is how the initial double-positive NANOG
85 and GATA6 cells respond differently to FGF signaling. It has been shown that
86 *Fgfr2*-null embryos died soon after implantation and failed to form a yolk sac
87 (14). Single-cell transcriptome analysis revealed that *Fgfr2* was more highly
88 expressed in PE progenitors than in EPI progenitors in E3.5 mouse
89 blastocysts, while expression of *Fgfr1* was similar in both. Expression of *Fgfr3*
90 and *Fgfr4* was also found to be higher in PE cells but only at the later
91 development stage E4.5 (15). Together, this data suggests that FGFR2 is
92 essential for the differential response of ICM cells in the early blastocyst.
93 However, mutational studies suggested that FGFR1 was critical for
94 establishing the PE lineage, with FGFR2 playing a later role in the
95 maintenance and stability of PE (16,17).

96 Since FGFR1 is present in all ICM cells (16,17), what leads to the
97 specific expression of FGFR2 in PE precursors? It was published that p38
98 activation under the control of FGF4 participates in PrE specification before
99 the E3.75 time point (18). The authors also showed a role for non-canonical

100 BMP signaling in the control of p38. Earlier, it was shown that inhibition of
101 BMP signaling would impact the formation of PrE (19), although not as
102 dramatically as MEK inhibition (12). In addition, single-cell transcriptome
103 analysis revealed concomitant increase in BMP4, FGF4, NANOG, and SOX2
104 expression in putative epiblast cells (Guo *et al.* 2010).

105 We then hypothesized that FGF4 and BMP4 positively influence
106 FGFR2 expression in PE progenitors. In this study, we used live imaging of
107 FGFR2-eGFP embryos to verify the spatio-temporal dynamics of FGFR2
108 expression and observed that in early blastocysts, FGFR2 was not detectable
109 in the ICM. We observed an increase in the correlation value between FGFR2
110 and GATA6 starting at the early blastocyst stage and continuing through to
111 the mid and late blastocyst stage. This pattern is accompanied by an
112 observed decrease in the correlation between NANOG and both FGFR2 and
113 GATA6. Experiments with either exogenous FGF4 or MEK inhibitors from
114 morula (E2.5) onwards did not influence the expression of FGFR2 in early
115 blastocysts (E3.25), but respectively increased or decreased the number of
116 FGFR2 positive cells at E3.5 and E4.5 embryos. Treatment with BMP4 from
117 morula up to E4.5 decreased the number of NANOG positive cells and
118 revealed a high correlation between FGFR2 and SOX17. Our results are
119 consistent with a role for FGFR2 in maintenance but not initiation of the PE
120 lineage.

121

122 **Material and Methods**

123

124 All animal work was performed following Canadian Council on Animal
125 Care Guidelines for Use of Animals in Research and Laboratory Animal Care
126 under Animal Use Protocol number 20–0026H, approved by The Centre for
127 Phenogenomics Animal Care Committee.

128

129 **FGFR2-eGFP mice generation**

130

131 G4 Mouse ES cells (129S6/SvEvTac x C57BL/6Ncr, George *et al.*
132 2007) were used to knock-in eGFP downstream of the endogenous FGFR2
133 gene. The targeting plasmid was constructed using a custom designed and
134 synthesized plasmid backbone containing a P2A-eGFP-SV40 NLS insert
135 followed by FRT-SV40pA-PGK promoter-Neo-bGHpA-FRT (Biobasics). 4.8
136 (5') and 3 kb (3') homology arms for Fgfr2 were amplified from a BAC clone
137 (RP23-332B13) and cloned into the targeting construct (homology arm and
138 insert sequence provided in Supplementary files S1 and S2). ES cells were
139 electroporated with the linearized targeting construct, Neomycin-selected, and
140 clonally expanded. Individual clones were genotyped using over the arm PCR
141 and single copy integration was validated using Southern blotting. Cells were
142 then aggregated with a host morula (CD-1 background) to generate chimeras
143 and transferred into pseudopregnant females. Resulting founder mice were
144 identified by coat color chimerism and bred for germ line transmission. F1
145 animals were subsequently genotyped, and crossed to FlpE expressing mice
146 to delete the Neomycin selection cassette (B6.Cg-Tg(ACTFLPe)9205Dym/J,
147 Rodríguez *et al.* 2000). Mice were bred until homozygous.

148

149

150 **Embryo collection and culture**

151

152 Mice were superovulated after administration 5IU of eCG (PMSG) I.P.
153 between 11:00h and 13:00h and 46-48h later, administering 5IU of hCG I.P.
154 to induce ovulation. Females were immediately placed with studs after hCG
155 injection. Around 8:00h next morning, females were checked for successful
156 mating based on vaginal plug observation and were then separated from
157 males. Mating was considered to have occurred at 00:00h, which
158 characterizes embryonic day 0 (E0.0). Females were euthanized by cervical
159 dislocation at E0.5, E1.5, E.2.5 or E3.5 according to the desired embryonic
160 stage for collection. Embryos at E0.5 were collected after tearing of the
161 ampulla using a 30G needle in M2 medium supplemented with 10 µg/ml of
162 hyaluronidase. Embryos at E1.5 and E2.5 were collected after flushing the
163 oviduct via the infundibulum using M2 medium. Embryos at E3.5 were
164 collected after flushing the uterus with M2 medium and fixed immediately or
165 cultured up to E3.75, E4.0, E4.25 and E4.5 in KSOM medium at 37°C and 5%
166 CO₂ prior to live imaging or fixation.

167

168 **Live imaging and time-lapse confocal microscopy**

169

170 Live imaging and time-lapse imaging of live embryos was performed in
171 a Quorum Spinning Disk Leica confocal microscope with the assistance of
172 Volocity software (Quorum Technologies, Guelph, ON, Canada). Embryos
173 were collected at different stages as described and placed in a M2 medium

174 drop on a Mat-Tek dish with glass bottom for immediate live imaging. For
175 time-lapse imaging, embryos were placed in KSOM drops covered with
176 mineral oil on a Mat-Tek dish at 37°C and 5% CO₂. The live cell-imaging
177 chamber (Chamlide, Live Cell Instrument, Namyangju-si, Korea) was placed
178 on the microscope stage at least 30 minutes before placing the embryos, to
179 equilibrate the system to 37°C and 5% CO₂. Glass tips from pulled pipettes
180 were used to contain the embryos and minimize embryo movement while
181 imaging. Embryos were then placed in the chamber for time-lapse imaging.
182 Time-lapse embryos were only imaged for 24-28h, in order to avoid
183 discrepancies that could arise from cell death after prolonged UV exposure.
184 Imaging was set for 1μm Z intervals, using maximum sample protection.
185 Laser power and exposure times were set to the minimum value that yielded a
186 robust eGFP signal (from 20-30 and 150-200ms, respectively) and sensitivity
187 was set to the maximum level. Instant live imaging allowed longer exposure
188 times to maximize eGFP signal.

189

190

191 **Immunofluorescence of FGFR2-eGFP embryos**

192

193 Embryos were retrieved from KSOM media and washed in M2 three
194 times before fixation. Embryos were fixed with 4%PFA after 15 minutes of
195 incubation at RT. PFA was prepared fresh daily or weekly and kept at 4°C.
196 After fixation, embryos were washed in 3 drops of PBS (Ca²⁺ and Mg²⁺-free)
197 supplemented with 1mg/ml of polyvinylpyrrolidone (PBS-PVP) and stored in
198 PBS-PVP at 4C. Before immunostaining, we removed the zona pellucida by

199 briefly incubating embryos in acidic Tyrode's solution followed by rinsing in
200 PBS-PVP supplemented with 1% BSA and 0.1% Triton X-100 (PBS-PVP-
201 BSA). Embryos were then permeabilized for 15 minutes using PBS
202 supplemented with 0.25% Triton X-100 in a Terasaki plate (Nunc,
203 ThermoFisher). After permeabilization, embryos were rinsed three times in
204 PBS-PV-BSA and incubated for 1h at RT in PBS-PVP supplemented with
205 10% donkey serum to block nonspecific antigens. Embryos were then
206 incubated with primary antibodies diluted in PBS-PVP-BSA at 4°C overnight.
207 Primary antibodies and their respective dilutions were as follows: mouse anti-
208 GFP (Thermo Fisher, A11120, 1:100), rabbit anti-NANOG (Cell Signalling
209 Technologies, 8822, 1:400), goat anti-GATA6 (R&D Systems, AF1700, 1:40)
210 or goat anti-SOX17 (R&D Systems, AF1924, 1:400). On the next day,
211 embryos were washed three times for 10 minutes in PBS-PVP-BSA and then
212 incubated with secondary antibodies diluted in PBS-PVP-BSA for 1h at RT.
213 Secondary antibodies and their respective dilutions were as follows: donkey
214 anti-mouse Dy488 (Jackson, 715-485-151, 1:400), donkey anti-rabbit AF647
215 (Thermo Fisher, A31573, 1:400), donkey anti-goat AF546 (Thermo Fisher,
216 A11056, 1:400). Embryos were washed three times for 10 minutes in PBS-
217 PVP-BSA and incubated with Hoechst 33342 10 µg/ml in PBS-PVP-BSA for
218 10 minutes. Embryos were then rinsed three times in a 1:100 solution of
219 Prolong live anti-fading reagent (P36975, ThermoFisher) diluted with PBS-
220 PVP-BSA. Embryos were then placed into a drop of 5µl of Prolong Live anti-
221 fading reagent solution on 100mm coverslips using an adhesive spacer
222 (S24737, ThermoFisher), allowing different treatment or stages to remain in
223 single drops. All immunostained embryos were evaluated under confocal

224 microscopy using a Quorum Spinning Disk Leica confocal microscope with
225 the assistance of Volocty software (Quorum Technologies, Guelph, ON,
226 Canada).

227

228 **Quantitative image analysis**

229 Immunostaining images were then analyzed by Image J software
230 (<https://imagej.nih.gov/ij/>; Schneider et al. 2012). Nuclei from the ICM were
231 identified and manually captured using the freehand selection tool at their
232 largest diameter. Fluorescence intensities were measured for all channels and
233 the decimal logarithmic value of mean pixel intensity was used for
234 downstream analysis. All intensities were plotted by respective Z stack and a
235 linear regression was performed to obtain the slope value. This slope value
236 was used to correct for fluorescence decay along the Z-axis as described
237 previously (22):

238 $Z\text{ Corrected Intensity} = \text{Original intensity} - (\text{Slope} \times Z\text{ stack})$

239 Corrected values were then subtracted by an average of two
240 background values, which were also corrected by the Z-axis position. These
241 values were then used to correlate pixel intensity of GFP, NANOG and
242 GATA6 or SOX17 staining.

243

244

245 **Treatment with FGF or MEK inhibitor**

246

247 FGFR2-eGFP embryos collected at E2.5 were cultured in KSOM drops
248 at 37°C and 5% CO₂. Embryos were untreated or treated with 500 ng/μl

249 FGF4 and 1 μ g/ml heparin or 0.5mM MEK inhibitor PD325901 (MEKi) for 24h
250 (E3.5), 30h (E3.75) or 48h (E4.5). Embryos were live imaged to observe
251 FGFR2-eGFP or fixed and stained for NANOG and GATA6 as described
252 above. GFP-positive cells in the ICM were counted using Image J.

253

254 **Treatment with BMP4 or BMP inhibitors**

255

256 FGFR2-eGFP embryos collected at E2.5 were cultured in KSOM drops
257 at 37°C and 5% CO2. Embryos were left untreated or treated with 300 ng/ml
258 BMP4 for 24h (E3.5), 30h (E3.75) or 48h (E4.5). Embryos were fixed and
259 stained for NANOG, GATA6 or SOX17, and GFP as described above.
260 NANOG and GATA6 or SOX17-positive cells were counted and fluorescence
261 intensity of NANOG, GATA6 or SOX17 and GFP was measured in Image J as
262 described above. In a different experiment, embryos were left untreated or
263 treated with 500 nM (5Z)-7-oxozeaenol (7-oxo) or 1 μ M dorsomorphin (Dorso)
264 from E2.5 to E4.5 (48h) and NANOG and SOX17-positive cells were counted.

265

266 **Statistical analysis**

267

268 Linear regression and Pearson correlation analysis were performed
269 using GraphPad Prism7 software (GraphPad Software, Inc; San Diego, CA,
270 USA). We analyzed cell count data by ANOVA using PROC GLM of SAS 9.4,
271 considering embryos as subjects, treatments as the independent variable and
272 cell count as a dependent variable, followed by Tukey's comparison of means.
273 We also used PROC GLM of SAS 9.4 and Tukey's to analyze fluorescence

274 intensity, considering cells as subjects, treatments as independent variables
275 and intensity as the dependent variable.

276

277 **Results**

278

279 **Live dynamics of FGFR2 throughout pre-implantation development**

280

281 We characterized the FGFR2-eGFP reporter expression by collecting
282 embryos at different time points and performing live imaging using a spinning
283 disk confocal. We observed green nuclear fluorescence beginning at E2.5 in
284 some 8-cell stage embryos. However, some 8-cell embryos were still negative
285 for eGFP, which suggested that FGFR2 expression starts at the late 8-cell
286 stage. We observed eGFP expression at E3.0 in all outer cells of the morula
287 stage and within a small number of inner cells. However, at E3.5, eGFP was
288 only observed in the trophectoderm, while no clear nuclear localization of
289 eGFP was observed in the inner cell mass (ICM). At E4.5, nuclear eGFP was
290 seen in the ICM specifically in the cells closest to the blastocoel, where the
291 PE cells lie (Figure 1).

292 **Figure 1 - Dynamics of FGFR2-eGFP expression in mouse early embryo**
293 **development.** Representative images of homozygous FGFR2-eGFP
294 embryos live imaged at E2.5, E3.0, E3.5 and E4.5. Embryos were staged
295 based on morphology. Some 8-cell embryos were completely negative while
296 others displayed positive cells. Nuclear eGFP is observed broadly by the
297 morula stage. Early blastocysts display eGFP only in the TE, while expanded

298 blastocysts display GFP in ICM cells facing the blastocoel. Scale bar is equal
299 to 40 μ m.

300

301 To gain further insight on the dynamics of FGFR2-eGFP, we performed
302 time-lapse imaging of collected embryos. We imaged embryos from E1.5 to
303 E2.5, then E2.5 to E3.5 and E3.5 to E4.5. Time-lapse from E1.5 to E2.5
304 confirmed that nuclear eGFP appeared at late 8-cell stage (supplemental file
305 S3). From E2.5 to E3.5, most embryos had absent or reduced eGFP in inner
306 cells at the morula stage, leading to an ICM devoid of nuclear eGFP or with
307 few cells with very low eGFP intensity, especially when compared to the TE
308 (supplemental file S4). Similar observations were made when E3.5 was the
309 starting point, as most embryos still had little or weak GFP-positive cells in the
310 ICM but showed strong expression in the TE. After 12-16h in culture, a
311 stronger eGFP signal was observed in the ICM and after 24h it was possible
312 to observe the sorting of GFP-positive PE cells in the ICM (supplemental file
313 S5).

314

315 **Correlation between FGFR2, NANOG and GATA6**

316

317 Since there was no clear observation of eGFP-positive cells in the early
318 blastocyst, we decided to use a quantitative approach to assess if there is any
319 relationship between FGFR2 and NANOG or GATA6 protein expression. We
320 first grouped embryos by embryonic day: E3.5 (n=66 cells); E3.75 (n=125);
321 E4.0 (n=119); E4.25 (n=101) and E4.5 (n=107). Then we performed linear
322 regression analysis on data obtained by quantitative image analysis from

323 immunostaining of GFP, NANOG and GATA6 (Figure 2A). It is noticeable
324 over time that the correlation values for GFP and NANOG become negative
325 while GFP and GATA6 correlation values increase (Figure 2B). Pearson
326 correlation analysis revealed an increase at E3.75, but overall it showed a
327 decrease in the correlation of GFP and NANOG over time. Correlation
328 between GFP and GATA6 increased as early as E3.75 and remained higher
329 until E4.5 (Figure 2B). Pearson correlation analysis revealed a decrease in
330 the correlation of NANOG and GATA6 over time, with the largest changes in
331 correlation occurring at E3.75 and E4.25 (Figure 2B). Pearson correlation
332 values and p-values are listed in Table 1. Linear regression analysis reveals
333 the opposite trend in the relationship between NANOG or GATA6 with GFP
334 (Figure 2C). We also plotted data based on NANOG and GATA6 fluorescence
335 intensities. It was possible to observe a separation of cell populations over
336 time, as cells were grouped in one cluster at E3.5 and two clusters can be
337 observed at E4.25 and E4.5 (Figure 2D).

338 **Figure 2 - Correlation of FGFR2-eGFP, NANOG and GATA6 based on**
339 **embryonic day.** A) Representative images of homozygous FGFR2-eGFP
340 embryos at different embryonic days after immunostaining against GFP,
341 NANOG and GATA6. Scale bar is equal to 40 μ m. B) Graphic representation
342 of Pearson correlation values observed from E3.5 to E4.5. Blue dots
343 represents GFP and NANOG correlation, red squares represent GFP and
344 GATA6 correlation and green triangles represent NANOG and GATA6
345 correlation. C) Graphic representation of linear regression analysis of
346 fluorescence intensity levels. Blue dots and blue line represents NANOG cell
347 measurements and regression analysis considering NANOG and GFP levels

348 respectively. Red dots and red line represents GATA6 cell measurements and
349 regression analysis considering GATA6 and GFP levels respectively. D) Dot
350 plots depicting measured levels of NANOG and GATA6 in individual cells.

351 **Table 1 - Pearson correlation values and respective two-tailed p-values**
352 **of FGFR2-eGFP, NANOG and GATA6 fluorescence based on embryonic**
353 **day.**

	FGFR2eGFP: NANOG		FGFR2eGFP:GATA6		NANOG:GATA6	
	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value
E3.5	-0,2195	0,0766	0,1272	0,3088	0,1723	0,1667
E3.75	-0,1261	0,161	0,721	< 0.0001	-0,3203	0,0003
E4.0	-0,3445	0,0001	0,4731	< 0.0001	-0,3503	< 0.0001
E4.25	-0,6554	< 0.0001	0,7593	< 0.0001	-0,76	< 0.0001
E4.5	-0,5599	< 0.0001	0,7445	< 0.0001	-0,5078	< 0.0001

354
355 We then grouped embryos based on embryo staging by cell number:
356 32-64 (n=111 cells); 65-90 (n=196); 91-120 (n=139) and 121-150 (n=65).
357 Linear regression analysis was performed as above and as embryos grew
358 larger, a similar trend was observed when compared to embryonic day
359 staging. Pearson correlation analysis revealed a more linear decrease in
360 correlation between GFP and NANOG and also a more linear increase in
361 correlation between GFP and GATA6, again with the largest change occurring
362 early, at the 65- to the 90-cell stage (Figure 3A). The correlation of NANOG
363 and GATA6 also revealed a negative trend with the largest change occurring
364 in 65 to 90-cell embryos (Figure 3A). Pearson correlation values and p-values
365 based on embryo staging are listed in Table 2. Similar to data obtained by
366 embryonic day grouping, linear regression analysis reveals the opposite trend

367 in the relationship between NANOG and GFP compared to GATA6 and GFP
368 (Figure 3B). Again, we plotted data based on NANOG and GATA6 results and
369 separation of the two cell populations occurred in 91 to 120-cell and 121 to
370 150-cell embryos (Figure 3C).

371 **Figure 3 - Correlation of FGFR2-eGFP, NANOG and GATA6 based on cell**
372 **number.** A) Graphic representation of Pearson correlation values observed in
373 embryos with 32 to 64 cells, 65 to 90 cells, 91-120 cells and 121-150 cells.
374 Blue dots represents GFP and NANOG correlation, red squares represent
375 GFP and GATA6 correlation and green triangles represent NANOG and
376 GATA6 correlation. B) Graphic representation of linear regression analysis of
377 fluorescence intensity levels. Blue dots and blue line represents NANOG cell
378 measurements and regression analysis considering NANOG and GFP levels
379 respectively. Red dots and red line represents GATA6 cell measurements and
380 regression analysis considering GATA6 and GFP levels respectively. C) Dot
381 plots depicting measured levels of NANOG and GATA6 in individual cells.

382 **Table 2 - Pearson correlation values and respective two-tailed p-values**
383 **of FGFR2-eGFP, NANOG and GATA6 fluorescence based on embryo cell**
384 **number.**

	FGFR2eGFP: NANOG		FGFR2eGFP:GATA6		NANOG:GATA6	
	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value
32-64	0,01061	0,912	0,3617	< 0.0001	0,2847	0,0025
65-90	-0,1379	0,0539	0,6668	< 0.0001	-0,3606	< 0.0001
91-120	-0,4626	< 0.0001	0,6966	< 0.0001	-0,4901	< 0.0001
121-150	-0,4199	0,0005	0,8676	< 0.0001	-0,5447	< 0.0001

385

386

387

388 **FGFR2 response to FGF or MEK inhibition**

389

390 To assess the relationship between FGF4 signalling and FGFR2 we
391 stimulated the FGF pathway or inhibited MEK signalling from E2.5 to E3.5,
392 E3.75 or E4.5. We assessed live FGFR2-eGFP expression or NANOG and
393 GATA6 expression by immunostaining. At E3.5, no FGFR2-eGFP was
394 observed in the ICM in all three conditions (Figure 4A) Also, mutual
395 expression of NANOG and GATA6 was observed in most of the cells in all
396 three conditions (Figure 4B). At E3.75 and E4.5, GFP staining was weaker in
397 MEKi-treated embryos (Figure 4A). FGF4 treated embryos displayed only
398 GATA6 cells in the ICM, while MEKi treated embryos displayed only NANOG
399 cells in the ICM, as expected (Figure 4B). We then counted FGFR2-eGFP-
400 positive cells (E3.5 Control n=9 embryos, FGF4 n=8, MEKi n=12; E3.75
401 Control n=12, FGF4 n=11, MEKi n=4; E4.5 Control n=12, FGF4 n=8, MEKi
402 n=10) and confirmed that FGF4 treatment increased FGFR2-eGFP cells from
403 E3.75 onwards, and MEKi reduced the number of FGFR2-eGFP-positive cells
404 at E4.5 (Figure 4C).

405 **Figure 4 - Treatment of FGFR2-eGFP embryos with FGF4 or ERK
406 inhibitor.** A) Representative images of live imaged FGFR2-eGFP embryos at
407 different embryonic days and consequently different exposure to treatment.
408 Scale bar is equal to 47 μ m. B) Representative images of embryos
409 immunostained for NANOG (grey) and GATA6 (red) at different embryonic
410 days and consequently different exposure to treatment. Scale bar is equal to
411 47 μ m. C) Graphical display of GFP cell counts in the ICM at E3.5, E3.75 and

412 E4.5. Letters within each timepoint indicates statistical significance, as "a"
413 indicates significant differences from all other groups and "b" indicates
414 significant differences from MEKi group.

415

416 **FGFR2 response to BMP4 or BMP inhibition**

417

418 We then opted to assess the effects of BMP4 on FGFR2 expression.
419 BMP4 was added from E2.5 to E4.5. Embryos were fixed for immunostaining
420 for GFP, NANOG and GATA6 from E3.5 to E3.75 or SOX17 at E4.5. Unlike
421 FGF treatment, there is no drastic effect on the epiblast and PE cell
422 population (Figure 5A). We then counted cells (Control n=11, BMP4 n=13
423 embryos) and observed a reduction in NANOG-positive cell numbers,
424 although no increase in SOX17 cells (Figure 5C). We then performed
425 quantitative image analysis (Control n=229 cells, BMP n=219 cells) from
426 immunostaining and found that BMP increased fluorescence intensity of
427 FGFR2-eGFP at 3.75 and E4.5 (Figure 5D). Pearson correlation analysis
428 revealed that FGFR2-eGFP and SOX17 had a much higher correlation after
429 BMP treatment (Figure 5B). Moreover, the negative correlation of FGFR2-
430 eGFP and NANOG was more accentuated after BMP treatment (Figure 5B).

431 **Figure 5 - Treatment of FGFR2-eGFP embryos with BMP4.** A)
432 Representative images of embryos from each experimental group after
433 immunostaining for GFP, NANOG and SOX17. B) Graphic representation of
434 Pearson correlation values between GFP, NANOG and SOX17 after BMP
435 treatment. Blue lozenges represent values from Control group while red
436 squares represent values from BMP treated group. C) Graphic representation

437 of cell counts in embryos after treatments for different times. D) Graphic
438 representation of quantitative image analysis after immunostaining of GFP,
439 NANOG and GATA6 or SOX17. Asterisk denotes significant statistical
440 difference.

441

442 On the other hand, treatment with BMP signaling inhibitors (Control
443 n=16 embryos, 7-oxo n=15, Dorsomorphin n= 16 embryos) did not change the
444 numbers of NANOG-, SOX17- or FGFR2-eGFP-positive cells (Figure 6A and
445 6C). Quantitative image analysis (Control n=64 cells, 7-oxo n=61 cells, Dorso
446 n=67 cells) revealed an increase in NANOG, SOX17, and FGFR2-eGFP
447 fluorescence intensities after 7-oxo. Since this increase occurred in all three
448 variables measured, the correlation between these variables followed the
449 same trend in each treatment (Figure 6B), suggesting no effect of BMP
450 inhibition on the differentiation of the PE.

451 **Figure 6 - Treatment of FGFR2-eGFP embryos with BMP signaling**
452 **inhibitors.** A) Representative images of embryos from each treatment group
453 at E4.5 after immunostaining for GFP, NANOG and SOX17. B) Graphic
454 representation of Pearson correlation values between GFP, NANOG and
455 SOX17 after BMP inhibitors treatment. Blue lozenges represent values from
456 Control group, red squares represent values from 7- oxozeaenol treated
457 group and green triangles represent values from dorsomorphin treated
458 embryos. C) Graphic representation of cell counts in E4.5 embryos after
459 different treatments. D) Graphic representation of quantitative image analysis
460 after immunostaining of GFP, NANOG and SOX17. Different superscript
461 letters denotes significant statistical difference between groups.

462

463 **Discussion**

464

465 Studying the segregation of epiblast and primitive endoderm can
466 elucidate mechanisms of regulative development in mammalian embryos.
467 MEK/ERK signaling stimulated by FGF is pivotal in determining cell fate within
468 the ICM, leading to the specification of the PE (12). Using a transgenic mouse
469 model expressing an eGFP reporter we observed the dynamics of FGFR2
470 expression during early embryo development, to correlate its expression with
471 the segregation of the two ICM lineages.

472 Observing live embryos at different time points, we observed that
473 expression of FGFR2 starts at the late 8-cell stage but does not include all
474 cells at the 8-16 cell stage. By the blastocyst stage, the TE showed robust
475 expression of FGFR2-GFP, consistent with its role in TE expansion and
476 formation of the blastocoel (23). Interestingly, in the early blastocyst, none or
477 very few cells in the ICM displayed FGFR2-eGFP; this contrasts with the
478 reported E3.25 ICM *Fgfr2* RNA expression data (15), suggesting a possible
479 post-transcriptional regulation of *Fgfr2* in ICM cells. FGFR2-eGFP only
480 appeared in the ICM at later blastocyst stages. These results match with
481 FGFR2 detection by immunofluorescence (24) and with another study using a
482 FGFR2 fluorescent reporter (16)

483 Studies showed that deletion of *Fgfr1* impacted PE specification more
484 severely than *Fgfr2* deletion, implicating that FGFR2 would be mainly involved
485 with PE cell survival and proliferation (16,17). *Fgfr1*-null embryos treated with
486 exogenous FGF4 did not recover PE formation, while *Fgfr2*-null embryos

487 could form PE after exogenous FGF4 treatment (16,17); this agrees with the
488 absence or reduced presence of FGFR2-eGFP in early blastocysts,
489 corroborating that FGFR2 indeed is secondary to FGFR1 in PE specification.
490 In addition, a weak association of FGFR2-eGFP with GATA6 at the early
491 blastocyst and the most significant increase in correlation between FGFR2-
492 eGFP and GATA6 seen after the early blastocyst stage reiterates that FGFR2
493 is not the initial receptor for FGF4 signaling during PE specification. The
494 developmental dynamics of the correlations between NANOG and FGFR2-
495 eGFP or GATA6 and FGFR2-eGFP agree with the timing in which the number
496 of double-positive cells starts to diminish and either NANOG- or GATA6-
497 positive only cells emerge (25).

498 These data combined suggest an event or series of events that lead to
499 these changes in the ICM from early blastocyst to the blastocyst stage. We
500 decided to test if exogenous FGF4 stimulation or inhibition at earlier stages
501 would affect FGFR2-eGFP expression in the early blastocyst. At E3.5, after
502 24h of treatment, no changes in FGFR2-eGFP were observed in embryos
503 treated with FGF4 or MEK inhibitor, suggesting that the FGFR2 upregulation
504 at the early blastocyst stage is independent of FGF signaling. This is
505 corroborated by the fact that *Fgfr2* expression is unchanged in *Fgfr1*-null mice
506 (17).

507 The data on the more prominent role of FGFR1 in PE specification
508 does not undermine the importance of FGFR2 since *Fgfr2*-null mice present
509 reduced number of PE cells in the ICM (16,17). The addition of FGFR2 may
510 allow cells to have a more robust activation of ERK (26), leading to PE
511 commitment. These data combined with the shift in correlation between

512 NANOG:GATA6 and GATA6:FGFR2-eGFP observed at E3.75 or 65-90 cells,
513 prompted us to hypothesize that some other signaling molecule could induce
514 FGFR2 expression.

515 Based on previous results (18,19), we tested if BMP signaling would be
516 involved in regulating FGFR2 expression in this window of time. Results
517 showed that FGFR2-eGFP was increased after BMP treatment at E3.75,
518 although changes in EPI cell number were only observed at E4.5. No changes
519 were observed from E2.5 to E3.5; this is in agreement with a proposed
520 window of p38-MAPK activity soon after E3.5, which would ensure PE
521 specification (27) through BMP signaling (18).

522 In summary, we observed that FGFR2 appeared at the late 8-cell
523 stage, but its presence in the ICM of the early blastocyst is absent or reduced.
524 As the blastocyst develops further, FGFR2 becomes expressed specifically in
525 PE precursors within the ICM, as determined by the progressively increasing
526 positive correlation with GATA6 expression and negative correlation with
527 NANOG expression. Only this latest expression pattern is responsive to
528 changes in overall FGF signaling levels. BMP stimulation also had little effect
529 on EPI or PE cell numbers at earlier stages, only increasing FGFR2-eGFP
530 from E3.75 onwards and reducing NANOG cells at E4.5. Thus, we conclude
531 that FGFR2 is weakly associated with PE specification at the early blastocyst,
532 but highly associated with PE lineage maintenance after the initial blastocyst
533 stage.

534

535

536 **Acknowledgements**

537

538 Authors would like to thank Marina Gertsenstein and the Transgenic
539 Core at Toronto Center for Phenogenomics for assistance in production of
540 transgenic animals.

541

542 **Funding Sources**

543

544 This work was funded by CIHR Foundation grant # FDN-143334 to JR.

545

546 **References**

547

- 548 1. Lawrence PA, Levine M. Mosaic and regulative development: two faces
549 of one coin. *Curr Biol*. 2006;16(7):236–9.
- 550 2. Gardner RL, Rossant J. Investigation of the fate of 4-5 day post-coitum
551 mouse inner cell mass cells by blastocyst injection. *J Embryol Exp
552 Morphol*. 1979;52:141–52.
- 553 3. Gardner RL. Investigation of cell lineage and differentiation in the
554 extraembryonic endoderm of the mouse embryo. *J Embryol Exp
555 Morphol*. 1982;68:175–98.
- 556 4. Chazaud C, Yamanaka Y, Pawson T, Rossant J. Early Lineage
557 Segregation between Epiblast and Primitive Endoderm in Mouse
558 Blastocysts through the Grb2-MAPK Pathway. *Dev Cell*.
559 2006;10(5):615–24.
- 560 5. Plusa B, Piliszek A, Frankenberg S, Artus J, Hadjantonakis A-K. Distinct
561 sequential cell behaviours direct primitive endoderm formation in the

562 mouse blastocyst. *Development*. 2008;135(18):3081–91.

563 6. Niakan KK, Ji H, Maehr R, Vokes SA, Rodolfa KT, Sherwood RI, et al.

564 Sox17 promotes differentiation in mouse embryonic stem cells by

565 directly regulating extraembryonic gene expression and indirectly

566 antagonizing self-renewal. *Genes Dev*. 2010;24(3):312–26.

567 7. Kang M, Piliszek A, Artus J, Hadjantonakis A-K. FGF4 is required for

568 lineage restriction and salt-and-pepper distribution of primitive

569 endoderm factors but not their initial expression in the mouse.

570 *Development* [Internet]. 2013;140(2):267–79. Available from:

571 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597205/>&too

572 l=pmcentrez&rendertype=abstract

573 8. Guo G, Huss M, Tong GQ, Wang C, Li Sun L, Clarke ND, et al.

574 Resolution of Cell Fate Decisions Revealed by Single-Cell Gene

575 Expression Analysis from Zygote to Blastocyst. *Dev Cell* [Internet].

576 2010;18(4):675–85. Available from:

577 <http://dx.doi.org/10.1016/j.devcel.2010.02.012>

578 9. Frankenberg S, Gerbe F, Bessonnard S, Belville C, Pouchin P, Bardot

579 O, et al. Primitive Endoderm Differentiates via a Three-Step Mechanism

580 Involving Nanog and RTK Signaling. *Dev Cell*. 2011;21(6):1005–13.

581 10. Schrode N, Saiz N, Di Talia S, Hadjantonakis AK. GATA6 levels

582 modulate primitive endoderm cell fate choice and timing in the mouse

583 blastocyst. *Dev Cell*. 2014;29(4):454–67.

584 11. Bessonnard S, De Mot L, Gonze D, Barriol M, Dennis C, Goldbeter A, et

585 al. Gata6, Nanog and Erk signaling control cell fate in the inner cell

586 mass through a tristable regulatory network. *Development* [Internet].

587 2014;141(19):3637–48. Available from:
588 <http://www.ncbi.nlm.nih.gov/pubmed/25209243>

589 12. Yamanaka Y, Lanner F, Rossant J. FGF signal-dependent segregation
590 of primitive endoderm and epiblast in the mouse blastocyst.
591 Development. 2010;137(5):715–24.

592 13. Kim SH, Kim MO, Cho YY, Yao K, Kim DJ, Jeong CH, et al. ERK1
593 phosphorylates Nanog to regulate protein stability and stem cell self-
594 renewal. Stem Cell Res [Internet]. 2014;13(1):1–11. Available from:
595 <http://dx.doi.org/10.1016/j.scr.2014.04.001>

596 14. Arman E, Haffner-Krausz R, Chen Y, Heath JK, Lonai P. Targeted
597 disruption of fibroblast growth factor (FGF) receptor 2 suggests a role
598 for FGF signaling in pregastrulation mammalian development. Proc Natl
599 Acad Sci U S A [Internet]. 1998;95(9):5082–7. Available from:
600 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC183133/>
601 pmcentrez&rendertype=abstract

602 15. Ohnishi Y, Huber W, Tsumura A, Kang M, Xenopoulos P, Kurimoto K,
603 et al. Cell-to-cell expression variability followed by signal reinforcement
604 progressively segregates early mouse lineages. Nat Cell Biol [Internet].
605 2014;16(1):27–37. Available from:
606 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970733/>
607 pmcentrez&rendertype=abstract

608 16. Molotkov A, Mazot P, Brewer JR, Cinalli RM, Soriano P. Distinct
609 Requirements for FGFR1 and FGFR2 in Primitive Endoderm
610 Development and Exit from Pluripotency. Dev Cell [Internet].
611 2017;41(5):511-526.e4. Available from:

612 <http://dx.doi.org/10.1016/j.devcel.2017.05.004>

613 17. Kang M, Garg V, Hadjantonakis AK. Lineage Establishment and
614 Progression within the Inner Cell Mass of the Mouse Blastocyst
615 Requires FGFR1 and FGFR2. *Dev Cell* [Internet]. 2017;41(5):496-
616 510.e5. Available from: <http://dx.doi.org/10.1016/j.devcel.2017.05.003>

617 18. Thamodaran V, Bruce AW. p38 (Mapk14/11) occupies a regulatory
618 node governing entry into primitive endoderm differentiation during
619 preimplantation mouse embryo development. *Open Biol* [Internet].
620 2016;6(9):160190. Available from:
621 <http://www.ncbi.nlm.nih.gov/pubmed/27605380> <http://www.ncbi.nlm.nih.gov/articlerender.fcgi?artid=PMC5043583> <http://www.ncbi.nlm.nih.gov/pubmed/27605380%5Cnhttp://rsob.royalsocietypublishing.org/lookup/doi/10.1098/rsob.160190>

625 19. Graham SJL, Wicher KB, Jedrusik A, Guo G, Herath W, Robson P, et
626 al. BMP signalling regulates the pre-implantation development of extra-
627 embryonic cell lineages in the mouse embryo. *Nat Commun* [Internet].
628 2014;5(May):5667. Available from:
629 <http://www.nature.com/doifinder/10.1038/ncomms6667>

630 20. George SHL, Gertsenstein M, Vintersten K, Korets-Smith E, Murphy J,
631 Stevens ME, et al. Developmental and adult phenotyping directly from
632 mutant embryonic stem cells. *Proc Natl Acad Sci* [Internet]. 2007 Mar
633 13;104(11):4455–60. Available from:
634 <https://pnas.org/doi/full/10.1073/pnas.0609277104>

635 21. Rodríguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, Ayala R,
636 et al. High-efficiency deleter mice show that FLPe is an alternative to

637 Cre-loxP. *Nat Genet* [Internet]. 2000 Jun;25(2):139–40. Available from:
638 http://www.nature.com/articles/ng0600_139

639 22. Saiz N, Kang M, Schrode N, Lou X, Hadjantonakis A-K. Quantitative
640 Analysis of Protein Expression to Study Lineage Specification in Mouse
641 Preimplantation Embryos. *J Vis Exp* [Internet]. 2016;(108):1–13.
642 Available from: [http://www.jove.com/video/53654/quantitative-analysis-
643 protein-expression-to-study-lineage](http://www.jove.com/video/53654/quantitative-analysis-protein-expression-to-study-lineage)

644 23. Yang J, Zhang D, Yu Y, Zhang RJ, Hu XL, Huang HF, et al. Binding of
645 FGF2 to FGFR2 in an autocrine mode in trophectoderm cells is
646 indispensable for mouse blastocyst formation through PKC-p38
647 pathway. *Cell Cycle*. 2015;14(20):3318–30.

648 24. Haffner-Krausz R, Gorivodsky M, Chen Y, Lonai P. Expression of Fgfr2
649 in the early mouse embryo indicates its involvement in preimplantation
650 development. *Mech Dev*. 1999;85(1–2):167–72.

651 25. Saiz N, Mora-Bitrià L, Rahman S, George H, Herder JP, García-Ojalvo
652 J, et al. Growth factor-mediated coupling between lineage size and cell
653 fate choice underlies robustness of mammalian development. *Elife*.
654 2020;9:1–38.

655 26. Simon CS, Rahman S, Raina D, Schröter C, Hadjantonakis AK. Live
656 Visualization of ERK Activity in the Mouse Blastocyst Reveals Lineage-
657 Specific Signaling Dynamics. *Dev Cell*. 2020;55(3):341–353.e5.

658 27. Bora P, Gahurova L, Mašek T, Hauserova A, Potěšil D, Jansova D, et
659 al. p38-MAPK-mediated translation regulation during early blastocyst
660 development is required for primitive endoderm differentiation in mice.
661 *Commun Biol*. 2021;4(1):788.

662 **Supplemental file legends**

663 **S1 file - DNA sequence of the plasmid used for homologous**
664 **recombination in ES cells**

665 **S2 file - Schematic representation of the plasmid used for homologous**
666 **recombination in ES cells**

667 **S3 file - Time-lapse imaging of live FGFR2-eGFP embryos from E1.5 to**
668 **E2.5**

669 **S4 file - Time-lapse imaging of live FGFR2-eGFP embryos from E2.5 to**
670 **E3.5**

671 **S5 file - Time-lapse imaging of live FGFR2-eGFP embryos from E3.5 to**
672 **E4.5**

673






Figure 1


A



B



C



D






Figure 2

A



B



C







Figure 3

A**B****C****Figure 4**








Figure 5

A**B****C****D****Figure 6**